What’s Next in Access & Affordability: A Biopharma Perspective

Sponsored by CoverMyMeds

As the healthcare landscape evolves, pharmaceutical manufacturers face increasing complexity in helping patients access and afford prescribed therapies. In this discussion, Megan Wetzel and Nicole Eckl of CoverMyMeds explore how the pace of innovation, growing specialty medication adoption, and expanding stakeholder expectations are reshaping patient access and affordability strategies.

The conversation examines why reducing friction across the patient journey has become a critical priority. Wetzel and Eckl discuss the importance of embedding electronic prior authorization (ePA), access, and affordability solutions directly into existing provider workflows rather than introducing additional tools that create administrative burden. By integrating technology where care teams already work, organizations can help streamline therapy initiation, improve efficiency, and support better patient experiences.

Wetzel and Eckl also highlight the need for scalable, flexible access strategies that evolve throughout a brand's lifecycle—from launch and coverage expansion to patient adherence and long-term support. As market conditions, patient needs, and healthcare dynamics continue to change, they emphasize that successful innovation requires adaptability, speed, and a focus on meeting patients, providers, and pharmaceutical brands where they are.